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Abstract
Backgound: All newly diagnosed HIV-infected patients in the Netherlands should be screened for latent
tuberculosis infection (LTBI) and offered preventive therapy if infected without evidence of active tuberculosis.
This guideline, endorsed by the national professional body of HIV physicians is in line with international
recommendations, and based on the increased risk of progression from LTBI to active tuberculosis in HIV-infected
patients. The objective of the study is to assess the intention of HIV physicians to implement this national guideline.
Methods: A mixed method design triangulating results from two surveys among all (n = 80) HIV physicians in The
Netherlands and qualitative interviews among 11 Dutch HIV physicians performed in 2014.
Results: The majority of physicians used a risk-stratification approach based on individual a priori risk of
tuberculosis to identify HIV-infected patients for LTBI screening, rather than screening all new HIV-infected patients.
The intended and actual provision of preventive treatment was low, due to expressed doubts on the accuracy of
diagnostic tools for LTBI. Interviewees reported that the guidelines did not match their clinical experience and
lacked evidence for the recommendations. Screening for and treatment of LTBI was approached at a patient-level
only. None of the interviewees referred to potential public health implications of the guidelines.
Conclusions: Intended implementation of the national HIV-TB guidelines in the Netherlands is poor, due to a
disconnect between clinical practice and evidence-based recommendations in the guideline. There is an urgent
need to reconcile the views of HIV-physicians, public health experts, and guideline committee members, regarding
the best strategy to address HIV-TB co-infection in the Netherlands.
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Background
In an attempt to reduce the risk of active tuberculosis
(TB), international guidelines stipulate screening HIV-
infected individuals for latent TB infection (LTBI), and
to offer preventive treatment if found infected and with-
out evidence of active TB [1, 2]. The World Health
Organization reinforces this strategy in its most recent
guideline for tuberculosis control [3].
Although combination antiretroviral therapy (cART)
has been shown to reduce the risk of developing TB in
HIV-infected individuals, the risk of TB in HIV-infected
individuals using cART remains higher compared to the
risk in non HIV-infected individuals [4]. Preventive ther-
apy in patients using cART has an independent and add-
itional effect on the reduction of TB in HIV-infected
patients [5], making LTBI screening and treating a
worthwhile strategy in countries with a good access and
uptake of ART.
There is no reference test for the diagnosis of LTBI.
The currently available tests assess the presence of an
interferon-gamma response after stimulation with Myco-
bacterium tuberculosis associated antigens in vivo (tu-
berculin skin test [TST]) or ex-vivo (Interferon-Gamma
Release Assay [IGRA]). Testing by TST is hampered in
immunosuppressed individuals due to possible anergy.
IGRA test were thought to overcome this issue and
therefore correlate better with the risk of progression to
active TB. However, in a large European cohort study
with more than 1700 patients with a wide variety of
types of immunosuppression such superiority of IGRA
over TST was not observed [6]. This equipoise makes
that several international guidelines recommend either a
two-step procedure (IGRA when TST-positive), or using
both test simultaneously [7, 8].
In the Netherlands, HIV care is only provided in 27
designated HIV treatment centers (HTC). These centers
are all in the public domain. HIV-physicians do provide
other care within the field of internal medicine. All HIV
physicians can be easily identified and approached, ei-
ther through the designated HTC or through their pro-
fessional body (Netherlands Association for HIV
physicians [NVHB]. Treatment of patients with TB is in
close collaboration with TB-experts in the Municipal
Public Health Services throughout the country, regard-
less where the initial TB diagnosis is made. These ser-
vices provide their support and expertise during the full
duration of TB treatment.
In 2014, over 21,000 HIV-infected patients were regis-
tered, of whom 80 % were under clinical observation [9].
The Netherlands is considered to be a low incidence
country with regards to tuberculosis, reporting an inci-
dence of 1.9 per 100,000 population in 2014 [10]. The
Commission for Practical Tuberculosis Control devel-
oped a national HIV-TB guideline which states that all
newly diagnosed HIV-infected individuals should be
screened for LTBI using both TST and IGRA, and be
offered preventive therapy with nine months isoniazid
(5 mg/kg/day and a maximum dose of 300 mg) if
found infected without evidence of active TB (http://
www.nvalt.nl/service/richtlijnen/richtlijnen/richtlij-
nen3/tuberculose—hiv) [11]. These guidelines were
based on extensive systematic reviews and expert
panel discussions, and endorsed by all relevant profes-
sional (para)-clinical bodies. The recommendation on
the efficacy of and drug regimen for preventive treat-
ment in HIV-infected patients was based on a system-
atic review by Akolo et al. [12]. Anecdotal evidence
suggests that the recommendations regarding screen-
ing for and treatment of LTBI as defined in the
guideline are not widely implemented.
The aim of this study is to evaluate the intentional and
actual implementation of the Dutch HIV-TB guideline
recommendations with respect to screening for and
treatment of LTBI in newly diagnosed HIV-infected
patients.
Methods
We used an explanatory sequential mixed-methods de-
sign involving two phases [13]. First, a cross-sectional
survey was conducted to i) explore the intention to
screen for LTBI, ii) explore the intention to initiate pre-
ventive therapy, and iii) explore factors influencing
intended guideline adherence. Second, in-depth inter-
views were held to thoroughly explore the survey find-
ings and to get an understanding of physicians’ attitude
and actual practice with regard to LTBI screening and
treatment and the HIV-TB guideline. Data were col-
lected between January and May 2014. A detailed de-
scription of the questionnaires and interview guide can
be found in the Additional file 1.
Quantitative study
Quantitative data were collected through two cross-
sectional surveys using questionnaires. The first question-
naire (”intention questionnaire”) assessed the intention to
screen and treat for LTBI. It contained five hypothetical
HIV-infected patient histories to assess the intention to
screen for LTBI (screening cases [SC]). The histories were
characteristic for specific risks for TB in HIV-infected in-
dividuals, and chosen to highlight the underlying evidence
of the HIV-TB guidelines (Table 1). The intention to initi-
ate preventive therapy given a specific screening result
was assessed by formulating four treatment cases (TC)
(Table 1). Responses to both screening and treatment sce-
narios was scored as yes/no/do not know. The question-
naire was self-administered and returned anonymously.
The second questionnaire (“barrier questionnaire”) con-
tained 22 statements on factors potentially influencing
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intended guideline adherence in line with the concep-
tual framework (Fig. 1). Statements could be answered
with yes/neutral/no. Also this questionnaire was self-
administered and could be returned (anonymously) by
postal mail or email. The need for this information
was identified very shortly after the initial results of
the first questionnaire were received.
The “intention questionnaire” was distributed, filled-
in, and collected among the participants of the half-
yearly meeting of the NVHB. The “barrier questionnaire”
was sent to key persons in all HTC’s in the country with
the request to distribute it among all HIV physicians in
the facility, with several reminders by mail and phone to
do so. The initial “intention questionnaire” was added to
the distributed “barrier questionnaire” to give HIV phy-
sicians not present at the half-yearly NVHB meeting the
opportunity to respond to the “intention questionnaire”.
Following this approach, both questionnaires reached
all 80 HIV-physicians in the country. The quantitative
data from the questionnaires were analyzed with SPSS
(version 22). Outcomes are reported as frequencies
and percentages.
Qualitative study
Qualitative data were collected through in-depth inter-
views with experienced HIV-physicians from HTCs to
map factors influencing actual guideline adherence. The
interview guide for these interviews was developed
alongside the conduct of the quantitative surveys. Pre-
liminary survey results were used as input for the inter-
view guide which allowed us to get a more thorough
understanding of the survey findings during the inter-
views. The interview guide was slightly adjusted after the
analysis of the initial analysis of the surveys in order to
obtain more specific information. In consecutive inter-
views, physicians were asked if they recognized specific
issues identified through the surveys if they did not raise
these issues themselves.
The in-depth and semi-structured interviews used a
conceptual framework based on the Theory of Planned
Behavior (TPB), which states that behavior is determined
by a person’s behavioral intention and perceived behav-
ioral control (or self-efficacy) [14]. We adapted the TPB
model to fit the subject of medical guideline adherence.
The original TPB concepts (attitude, subjective norm
and perceived behavioral control) were reformulated to
fit our research question, based on a literature study
identifying factors influencing physicians’ guideline ad-
herence in general and specifically for HIV-TB. This re-
sulted in four main categories: i) guideline, ii) patient,
iii) physician, and iv) environmental factors. By doing so,
restructured categories relate better to daily clinical
Table 1 Description of screening (SC) and treatment (TC)
scenarios
Screening scenario
SC I Liberian man, 36 years, 3 months in The Netherlands,
CD4 count 360/mm3
SC II Liberian man, 36 years, 3 months in The Netherlands,
CD4 count 90/mm3
SC III Dutch woman, 42 years, intravenous drug use,
CD4 count 450/mm3
SC IV Dutch homosexual man, 26 years, CD4 count 20/mm3
SC V Dutch heterosexual woman, 32 years, CD4 count 200/mm3
Treatment scenario
TC I TST positive (7 mm)
TC II IGRA positive, TST negative (0 mm)
TC III IGRA positive, TST positive (16 mm)
TC IV IGRA negative, TST positive (16 mm)
Fig. 1 Theoretical framework used in study. Left: original description of Theopy of Planned Behavior (Ajzen et al [14]); Right: restructured
framework to accommodate the assessment of a medical guideline
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practice, and facilitate a targeted approach when ad-
dressing potential barriers. Furthermore, factors influen-
cing the intention to adhere to the guideline (behavioral
intention) were separated from factors influencing the
actual use of the guideline (behavior). These latter fac-
tors are categorized under environmental factors. The
general TPB framework remains the foundation of our
conceptual framework: various sources of attitudes, sub-
jective norms and measures of perceived behavioral con-
trol lead to an intent to behave and to potential
behavior. Figure 1 depicts the original TBP model and
our restructured model.
The interviews were conducted face-to-face, recorded,
transcribed verbatim, and subjected to member check
[15]. The study sample for the qualitative study was a
convenience sample including experienced physicians,
although care was taken to have a reliable spread with
regards the geographic region, age, and work environ-
ment. The transcripts of the interviews were coded using
thematic analysis by Braun and Clarke [16]. The coding
scheme was developed using a semi-inductive approach,
in which core themes were derived from the conceptual
framework. The scheme was completed by themes that
emerged during the analysis of the first two interviews.
An iterative approach was used for the analysis of the
qualitative data and terminated when saturation of the
data was reached [17]. Themes were identified from the
verbatim transcriptions and collected in an Excel work-
sheet, after which a manual appraisal of the themes and
their frequency was conducted.
Ethical approval
No ethical approval from the Netherlands Central
Committee on Research Involving Human Subjects
(CCMO) was needed. Dutch law states that “research
which requires filling in a questionnaire just once
generally does not fall under the scope of the Medical
Research Involving Human Subjects Act (WMO)”, unless
the “questions are detailed, burdensome, or intimate”
(http://www.ccmo.nl/en/questionnaire-research). The Dutch
law clearly states that therefore there is no need for
an approval by a Medical Ethical Review Committee
(METC). Mitigating circumstances that require METC
approval despite not needing CCMO approval include
the use of stored body material or issues arising
under the Law on Medical Treatment Agreement
(WGBO), which ensures an open and fair relationship
between patient and physician. The interviewees not
being patients and the absence of collecting body ma-
terial, the mitigating reasons for METC approval are
not present. With a written informed consent by each
of the interviewees, a proper ethical standard under
Dutch law for the study has been met.
Results
Quantitative study
Fifty-one of the 80 (64 %) “intention questionnaires”,
and 24 (30 %) “barrier questionnaires“were returned.
Eleven physicians, five females and six males, partici-
pated in an in-depth interview. They were from nine dif-
ferent hospitals from five cities (two small, three large).
Their age varied between 40 and 61 years. The years of
experience in the HIV-care varied between 10 and
29 years.
HIV-physicians intended to screen more frequently for
LTBI in scenarios representing HIV-infected patients
from Liberia, than Dutch HIV-positive patients, regard-
less of CD4 cell count (SC I: 38/51, 75 %, and SC II: 27/
51, 53 %, versus SC IV: 15/51, 29 %, and SC V: 23/51,
40 %). The only exception is the frequent intention to
screen when the Dutch HIV-infected patient is an intra-
venous drug user (SC III: 40/51, 78 %) (Fig. 2 Upper
left). Although low CD4 count is a risk for progression
from LTBI to active TB, respondents from both coun-
tries were less likely to be screened for LTBI in this set-
ting (SC II: 27/51, 53 %, SC IV 15/51, 20 %), compared
to those with high CD4 counts (SC I: 38/51, 75 %, and
SC III: 40/51, 78 % and SC V: 23/51, 40 %, respectively).
Of the 51 respondents, 12 (24 %) intended to screen for
LTBI in all SCs as the guideline stipulates. Of the HIV-
physicians who intended to screen for LTBI, less than
25 % would use both screening tests, as stipulated in the
guideline, in any of the SCs (Fig. 2 Upper right).
HIV-physicians were less inclined to initiate preventive
treatment in the treatment scenarios with an absent
IGRA (TC I: 21/51, 41 %) or a negative IGRA (TC IV:
22/51, 43 %). When both IGRA and TST were positive
(TC III), the majority (39/51, 76 %) of the HIV-
physicians intended to initiate preventive treatment
(Fig. 2 Lower left). One in five of the HIV physicians
would not initiate preventive treatment in any of the
treatment scenarios.
Responses to the statements relating to barriers and
facilitators for guideline implementation are reported in
Fig. 3.
Physician factors
The respondents answered in general neutrally on ques-
tions about their attitude towards the recommendations.
In contrast, 12 of the 24 (50 %) respondents gave an out-
spoken negative answer on the question whether the
guideline influenced their patient care (self-efficacy).
Guideline factors
Although almost none of the respondents considered the
recommendations to be unclear, inaccessible, conflicting
or insufficiently based on scientific evidence, only 21 %
(5/24) of the physicians reported the recommendations
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to correspond to the daily practice. Adequate involve-
ment with the formulation of the guideline (in person
or through the professional body) was reported by 46 %
(11/24) of the respondents, while 8 % (2/24) denied any
involvement at all.
Patient factors
The a priori risk for LTBI was reported to drive the deci-
sions regarding intended screening and treatment for
LTBI, according to 83 % (20/24) of the respondents,
while the clinical presentation of patients was a decisive
factor for 58 % (14/24) of the respondents. Although the
respondents reported that patients almost never refuse
screening for LTBI, they do sometimes refuse preventive
treatment.
Environmental factors
The large majority of the respondents (21/24, 88 %) re-
ported that resources for the execution of the recom-
mendations are available and accessible (time, space,
staff, equipment). There are no incentives for adherence
to the guideline. Four of the 24 (17 %) respondents
reported to have a view on screening and treatment of
LTBI that differed from their direct colleagues, indicat-
ing a large coherence within an HIV treatment facility.
Qualitative study
The interviews showed that most respondents were
aware of the HIV-TB guideline, but were not familiar
with the recommendation regarding LTBI screening in
all newly diagnosed HIV-infected patients. All inter-
viewees showed a much more negative attitude towards
the guideline than reported by the questionnaires, and
considered the recommendations to be aimless and
overdone, and none of the respondents adhered to it.
Actual non-adherence was driven by the conviction that
screening would not lead to extra health benefit, given
(i) the perceived low a priori risk for LTBI in the Dutch
population as the majority of HIV-infected individuals
being Dutch gay men, (ii) the preventive effect of cART
on the risk of TB, and (iii) the absence of actual TB
diagnoses in their own practice in HIV-infected patients
who are under regular follow-up. Other reasons for ac-
tual non-adherence included the fear of over-treating
Fig. 2 Intention to screen and start preventive therapy for hypothetical screening cases (SC) and treatment cases (TC). Definiton of SC and TC in
Table 1. Upper left: intention to screen for LTBI, Upper right: intention to use both TST and IGRA test to assess LTBI, Lower left: intention to start
preventive treatment if LTBI test positive without evidence of active TB
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patients, and the unreliability of the screening tests. The
value of doing both screening tests was contested by half
of the non-screening physicians, who would prefer IGRA
above TST because of its practical advantages and as-
sumed better test characteristics.
Physicians were reluctant to initiate preventive therapy
in HIV-infected patients on cART because of (i) the fear
of potential side-effects and drug-interactions; (ii) the
risk of over-treatment due the high amount of false posi-
tive test results, (iii) the perceived low risk that LTBI
would progress to active TB, and (iv) the fear of poor pa-
tient compliance and the short duration of protection
which could both increase the risk of drug-resistance.
Data triangulation
In general, the opinions expressed during the interviews
were more negative towards the underlying evidence for
the guideline, and its relationship with clinical practice
than elucidated from the questionnaires. Especially the
latter issue was reiterated several times during each
interview, and proved to be the driving force in institu-
tional discussions on the use of the guideline in daily
clinical work. The interviews identified in more detail
the reasons behind the preference of the IGRA test over
the TST in assessing LTBI, pointing strongly towards the
commonly known logistical limitations of the TST (pa-
tients need to return to have the test assessed). Triangu-
lation of the data elucidated the, commonly known,
arguments against the use of preventive treatment in
HIV-infected patients (side-effects, drug-interactions,
and patients’ adherence). The interviewees corroborated
the views on barriers to guideline implementation as
seen in the questionnaire. They reported to be confused
by multiple (inter)national guidelines, which are often
contradictory and not up-to-date. For example, the latest
version (2013) of the HIV-TB guideline, including the
recommendations on preventive therapy, had not yet
been posted on the website of the NVHB at the time of
the study (2014). The majority of the respondents had
missed a joint discussion on the guidelines within their
Fig. 3 Barriers and facilitators for intended guideline adherence by factors indentified in theoretical framework. Figures are percentages.
Upper left: physician factors; Upper right: guideline factors; Lower left: patient factors; Lower right: environmental factors
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professional body, potentially leading to a lack of con-
sensus about screening and treatment policies for LTBI.
Discussion
This study showed that Dutch HIV physicians have a
low intention to implement the HIV-TB guideline rec-
ommendations on screening for and treatment of LTBI.
Physician’s risk assessment on LTBI and progression to
active TB differs substantially from the risk assessment
used to underline the national (and international) guide-
lines. This mismatch does not imply poor clinical prac-
tice, as the study was not designed to be a clinical audit,
but solely an assessment of implementation.
A similar assessment of LTBI screening and treatment
practices has been reported by Wyndham-Thomas et al.
[18]. The study was carried out in Belgium, which is, just
as the Netherlands, a low-incidence country for tubercu-
losis, and showed similar findings. The authors reported
marked inconsistencies in screening and treatment ap-
proaches among HIV-physicians. Overall, just 20 % of
the physicians would screen for LTBI, and 14 % would
use both diagnostic test. Interestingly is that the authors
attribute these inconsistencies to the absence of up-to-
date guidelines. Our study shows that even with up-to-
date guidelines that are endorsed by the professional
body of HIV physicians, intended and actual adherence
is poor.
Data from the Swiss HIV Cohort Study showed that
physicians were more likely to screen HIV-infected pa-
tients with high a priori risks and high CD4 counts [19].
This cohort uses routine data and is therefore a useful
source to explore routine clinical behavior of HIV physi-
cians, even if studies are not directly designed to do so.
Our finding that even amongst high risk patients, re-
spondents were more frequently intended to screen for
LTBI in patients with high rather than low CD4 counts
can be explained by assuming that physicians are aware
of test limitations [12, 20, 21]. Despite differences in test
characteristics, it remains unclear how useful either test
(TST or IGRA) is in identifying those patients with im-
munosuppression at highest risk for progression to ac-
tive TB. The aforementioned study by Sester et al.
showed that neither TST, nor any of the IGRA tests had
this ability. Three out of 11 TB patients identified within
a period of two years after the initial test had a negative
test result for TST and two IGRAs [6]. A post-hoc ana-
lysis from the same study showed that actual HIV viral
load in plasma at the time of LTBI test performed better
in separating those with a higher risk of progression
from those with a low risk [22]. The results from our
questionnaire indicated that, if anything, respondents
had most faith in the results of an IGRA test in their de-
cision to start preventive therapy or not.
The finding of poor intended guideline implementa-
tion, and the actual non-adherence the guideline as re-
ported by the interviewees in our study agrees with
previous studies on adherence to clinical guidelines in
general, and guidelines specific for LTBI [23, 24]. Phys-
ician related barriers to intended and actual guideline
adherence included a lack of awareness of, and agree-
ment with the relevant recommendations [23, 25], lack
of self-efficacy [23], and absence of direct experience
with TB in their own practice [24]. The main guideline
related barriers were the perceived poor correspondence
of the guideline to daily practice, and the assumed low
quality and quantity of the scientific evidence presented
in the guideline. Such barriers affect heavily successful
implementation [26–28]. The strong negative attitude
towards the guidelines expressed during the interviews
was only partly validated by the results of the question-
naires, which makes interpretation difficult. Although
8 % of the survey respondents felt insufficiently involved
in the guideline development, almost all interviewees
complained about a lack of end-user involvement. In-
volvement of the end-user benefits guideline adherence
by an increased sense of ownership [26]. Representatives
from the professional group of HIV physicians were part
of the guideline committee from the start, while the
guidelines were presented, and adopted in one of the
half-yearly professional meetings.
The difference in intention to screen between HIV-
infected patients from Liberia and the Netherands is
most likely due to a perceived low a priori risk of LTBI
in Dutch HIV-infected patients. It is reported as one of
the most important patient-related barriers to guideline
adherence, as seen in other European countries [29].
The respondents thereby fail to acknowledge that miss-
ing a chance to prevent a case of TB has noticeable con-
sequences at the population level, given ongoing
transmission [30]. Almost one in three patients with pul-
monary TB in The Netherlands in 2014 had a patient
delay (onset cough to first visit care provider), while more
than one in four had a doctor’s delay (from first consult-
ation to start treatment) of more than 8 weeks [10].
The main strength of the study was a design enabling
data triangulation. The interviews confirmed the respon-
dents’ intended non-adherence to the guideline, and
enriched the data by giving insight in the actual attitude
towards the recommendations and reasons for non-
adherence. Adding the qualitative data to the results of
the questionnaires identified a deep resentment of HIV
physicians towards the guideline. Something that could
not be distilled from the questionnaires alone. This has
an impact on actions to be taken. Just discussing the
need for implementation is bound to fail when the re-
sentment toward the guideline is that deep. The triangu-
lation of the data makes that a renewed and rigorous
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discussion on the need, content, and implementation of
any HIV-TB guideline in The Netherlands is needed.
This discussion has started.
Solely relying on the results from a questionnaire in a
complex assessment like intended and actual clinical
management runs the risk of having data that are diffi-
cult to interpret. Such situation occurred in the study
from Belgium referenced earlier, in which almost one
third of the questionnaires had inconsistent answers
resulting from not following questionnaire guidance.
Although in practice domains used in the revised the-
oretical are likely not to be that clearly demarcated, the
framework provided a structure and enabled us in both
the quantitative and the qualitative study to disentangle
the different domains of potential factors influencing
intended and actual guideline adherence.
The main limitation of the study is the sub-optimal
sampling method. For the quantitative study, non-
response was solely due to not returning the question-
naires. Due to anonymity, we could not assess potential
bias in physicians responding and those not. The results
obtained from the questionnaire fit the anecdotal evi-
dence towards testing and treating of LTBI in the profes-
sional group, and covers practices in 19 of the 27 HIV-
treatment facilities in The Netherlands. Discussing the
findings with the HIV physicians strengthens our believe
that we were able to capture the prevailing opinions with
respect to intended screening and treatment behavior.
Although this can not serve as evidence for representa-
tiveness, it seems very unlikely that a different picture
would have emerged when a larger number of physicians
would have participated. The qualitative part of the study
uses a well-validated approach in which key-informants
are interviewed until responses are saturated. The choice
to use experienced HIV-physicians was taken to allow for
opinions known to have a strong impact on clinical
practice of younger colleagues. Screening and treatment
strategies are organized at an institutional level. Using
key informants gave us the opportunity to discuss these
approaches in detail. Despite these sources of potential
selection bias, we feel that the results accurately high-
light the level of intended and actual guideline imple-
mentation and the perceived barriers and facilitators to
implementation.
Conclusions
There is an urgent need for an in-depth discussion on
the perceived mismatch between clinical risk-assessment
by Dutch HIV-physicians, and the risk assessment based
on the scientific evidence used for the Dutch HIV-TB
guideline. Furthermore, the need, content and eventual
implementation strategy needs to be reconsidered by a
discussion between the guideline committee and the
professional body of HIV physicians.
Additional file
Additional file 1: Questionnaires and interview guide. (DOCX 21 kb)
Acknowledgements
The authors are grateful to Dr. E. Leijten who contributed to the description
of the screening and treatment cases used in the questionnaire.
Funding
None received.
Availability of data and materials
All data are used in the current analysis and described in the manuscript.
Questionnaires and interview guide are included as supplementary material.
Authors’ contributions
KE designed the study, collected and analyzed the data, and wrote the first
draft of the manuscript; FvL designed the study, analyzed the data, and
wrote all consecutive drafts and the final version; AV designed the study and
provided detailed commentary to the all versions of the manuscript. All
authors had access to the data, and read and approved the final version of
the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors agreed on publication.
Ethics approval and consent to participate
Not required under Dutch law (see extensive explanation in manuscript).
All interviewees provided written informed consent.
Author details
1Amsterdam Institute for Global Health and Development, Trinity Building C,
Pietersbergweg 17, 1105 BM Amsterdam, The Netherlands. 2Department of
Internal Medicine, Division of Infectious Diseases, Erasmus Medical Center,
Rotterdam, The Netherlands. 3Department of Global Health, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Received: 6 February 2016 Accepted: 17 August 2016
References
1. Pozniak AL, Coyne KM, Miller RF, Lipman MCI, Freedman AR, Ormerod LP, et al.
British HIV Association guidelines for the treatment of TB/HIV coinfection
2011. HIV Med. 2011;12:517–24.
2. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, et al. Guidelines
for prevention and treatment of opportunistic infections in HIV-infected
adults and adolescents: recommendations from CDC, the National Institutes
of Health, and the HIV Medicine Association of the Infectious Diseases
Society of America. MMWR Recomm Rep. 2009;58:1–207-4.
3. World Health Organization. Guidelines on the managment of latent
tuberculosis infection. Geneva: World Health Organization; 2015.
4. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients
receiving HAART: long term incidence and risk factors in a South African
cohort. AIDS. 2005;19:2109–16.
5. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G,
et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a
randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–90.
6. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG,
et al. Risk assessment of tuberculosis in immunocompromised patients. A
TBNET study. Am J Respir Crit Care Med. 2014;190:1168–76.
7. Clinical diagnosis and management of tuberculosis, and measures for its
prevention and control [Internet]. Manchester: National Institute for Health
and Care Excellence; 2011. Available from: https://www.nice.org.uk/
guidance/cg117/resources
8. Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, et al. Improved
sensitivity of an interferon-gamma release assay (T-SPOT.TBTM) in
Evenblij et al. BMC Public Health  (2016) 16:915 Page 8 of 9
combination with tuberculin skin test for the diagnosis of latent
tuberculosis in the presence of HIV co-infection. BMC Infect Dis. 2011;11:319.
9. van Sighem A, Gras L, Smit C, Stolte I, Reiss P. Monitoring of Human
Immunodeficiency Virus (HIV) in the Netherlands; monitoring report 2014.
Amsterdam: HIV Monitoring Foundation; 2014.
10. Slump E, Erkens CGM, van Hunen R, Schimmel HJ, van Soolingen D,
Teirlinck A, et al. Tuberculosis in The Netherlands 2014. Surveillance report.
Bilthoven: Rijksinstituut voor volksgezondheid en milieu; 2014.
11. van Leth F, Gebhart AC, van Altena R, Rijkeboer AA, Reusken AM, van
Gerven PJ. Practice guideline prevention, diagnosis and treatment of
tuberculosis in patients with an HIV infection. Ned Tijdschr Geneeskd.
2009;153:A1225.
12. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent
tuberculosis infection in HIV infected persons. Cochrane Database
Syst Rev. 2010;20(1):CD000171.
13. Greene JC, Caracelli VJ, Graham WF. Toward a conceptual framework for
mixed-method evaluation designs. Educ Eval Policy Anal. 1989;11:255–74.
14. Ajzen I. Theory of planned behavior. Organ Behav Hum Decis Process.
1991;50:179–211.
15. Barbour RS. Checklists for improving rigour in qualitative research: a case of
the tail wagging the dog? BMJ. 2001;322:1115–7.
16. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3:77–101.
17. Glaser B, Strauss A. The discovery of grounded theory: Strategies for
qualitative research. New York: Aldine; 1967.
18. Wyndham-Thomas C, Schepers K, Dirix V, Mascart F, Vooren J-P VAN,
Goffard J-C. Implementation of latent tuberculosis screening in HIV care
centres: evaluation in a low tuberculosis incidence setting. Epidemiol Infect.
2016;144:703–11.
19. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al.
Reducing tuberculosis incidence by tuberculin skin testing, preventive
treatment, and antiretroviral therapy in an area of low tuberculosis
transmission. Clin Infect Dis. 2007;44:94–102.
20. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al.
Interferon-gamma release assays for the diagnosis of latent tuberculosis
infection in HIV-infected individuals: a systematic review and meta-analysis.
J Acquir Immune Defic Syndr. 2011;56:230–8.
21. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of
tuberculosis and tuberculosis infection in HIV-infected adults: a systematic
review and meta-analysis. PLoS One. 2012;7:e32482.
22. Lange C, van Leth F, Sester M. TBnet. Viral Load and Risk of Tuberculosis in
HIV Infection. J Acquir Immune Defic Syndr. 2016;71:e51–3.
23. Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS. Why don’t
physicians adhere to guideline recommendations in practice? An analysis of
barriers among Dutch general practitioners. Implement Sci IS. 2009;4:54.
24. Chapman NH, Lazar SP, Fry M, Lassere MN, Chong BH. Clinicians adopting
evidence based guidelines: a case study with thromboprophylaxis. BMC
Health Serv Res. 2011;11:240.
25. DeRiemer K, Daley CL, Reingold AL. Preventing tuberculosis among HIV-
infected persons: a survey of physicians’ knowledge and practices. Prev
Med. 1999;28:437–44.
26. Grol R. Successes and failures in the implementation of evidence-based
guidelines for clinical practice. Med Care. 2001;39:II46–54.
27. Steinman MA, Sudore RL, Peterson CA, Harlow JB, Fried TR. Influence of
patient age and comorbid burden on clinician attitudes toward heart failure
guidelines. Am J Geriatr Pharmacother. 2012;10:211–8.
28. Solà I, Carrasco JM, Díaz Del Campo P, Gracia J, Orrego C, Martínez F, et al.
Attitudes and perceptions about clinical guidelines: a qualitative study with
Spanish physicians. PLoS One. 2014;9:e86065.
29. Pimpin L, Drumright LN, Kruijshaar ME, Abubakar I, Rice B, Delpech V, et al.
Tuberculosis and HIV co-infection in European Union and European
Economic Area countries. Eur Respir J. 2011;38:1382–92.
30. Mulder C, Harting J, Jansen N, Borgdorff MW, van Leth F. Adherence by
Dutch public health nurses to the national guidelines for tuberculosis
contact investigation. PLoS One. 2012;7:e49649.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Evenblij et al. BMC Public Health  (2016) 16:915 Page 9 of 9
